SUBSCRIBE TO OUR RSS
Companies lined up in the IPO Queue.
The Burrill Report
July 20, 2011
[Please login to post comments]
Expanding Access to Experimental ALS Drugs
Podcast: March 10, 2014
Study Casts Doubt on Benefits of the Medical Home
One long-running program led to little improvement in quality and no reduction in use of services or total costs.
Celgene Taps Abide Therapeutics for Enzyme Targeting Technology
Biotech will get $50 million, backers have potential exit.
Biotech Continues Hot Streak in U.S. Markets
Follow-on offerings top $1.7 billion in February; IPOs near $1 billion.
FDA Approves AstraZeneca Therapy for Rare Disease
Despite approval, agency plans to closely monitor therapy’s impact on patients with post-marketing studies.
A Transplant Bank Flush
Podcast: March 3, 2014
Actavis to Buy Forest Labs for $25 Billion
Combination would create a company with combined annual revenues of $15 billion.
Cell Therapy Shows Promise in Leukemia Battle
Genetically modified T cells induced complete remissions.
NBA Taps Wearable Tech to Track Player Vitals
League is turning to technology to fine-tune player performance.
The Case for Megamergers
Podcast: February 24, 2014
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER